CYTOTOXICITY MEDIATION OF CELLS EVIDENCING SURFACE EXPRESSION OF CD9

This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumours and tumour metastases), particularly to the mediation of cytotoxicity of tumour cells evidencing surface expression of CD9, and most particularly to the use of cancerous disease modifying antib...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CECHETTO, LISA M, FINDLAY, HELEN P, HANN, SUSAN E, YOUNG, DAVID S. F, FERRY, ALISON L
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumours and tumour metastases), particularly to the mediation of cytotoxicity of tumour cells evidencing surface expression of CD9, and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxms, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. Cette invention porte sur la stadification, le diagnostic et le traitement de maladies cancéreuses (à la fois de tumeurs primaires et de métastases de tumeur), en particulier sur la médiation de la cytotoxicité de cellules tumorales mettant en évidence l'expression de surface de CD9 et, de la façon la plus spécifique, sur l'utilisation d'anticorps modifiant une maladie cancéreuse (CDMAB), en combinaison facultative avec un ou plusieurs agents CDMAB/chimiothérapeutiques comme moyens d'initiation de la réponse cytotoxique. L'invention porte en outre sur des dosages de liaison qui utilisent le CDMAB de la présente invention. Les anticorps anti-cancer peuvent être conjugués à des toxines, des enzymes, des composés radioactifs, des cytokines, des interférons, des fractions cibles ou reporters et des cellules hématogènes.